Belite Bio Adr Stock Performance
| BLTE Stock | USD 67.73 0.04 0.06% |
Belite Bio has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.0636, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Belite Bio are expected to decrease at a much lower rate. During the bear market, Belite Bio is likely to outperform the market. Belite Bio ADR right now shows a risk of 2.77%. Please confirm Belite Bio ADR total risk alpha, expected short fall, market facilitation index, as well as the relationship between the value at risk and daily balance of power , to decide if Belite Bio ADR will be following its price patterns.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Belite Bio ADR are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Belite Bio may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
| Begin Period Cash Flow | 88.2 M |
Belite |
Belite Bio Relative Risk vs. Return Landscape
If you would invest 6,412 in Belite Bio ADR on December 20, 2024 and sell it today you would earn a total of 361.00 from holding Belite Bio ADR or generate 5.63% return on investment over 90 days. Belite Bio ADR is currently generating 0.129% in daily expected returns and assumes 2.7689% risk (volatility on return distribution) over the 90 days horizon. In different words, 24% of stocks are less volatile than Belite, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Belite Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Belite Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Belite Bio ADR, and traders can use it to determine the average amount a Belite Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0466
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | BLTE | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.77 actual daily | 24 76% of assets are more volatile |
Expected Return
| 0.13 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Belite Bio is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Belite Bio by adding it to a well-diversified portfolio.
Belite Bio Fundamentals Growth
Belite Stock prices reflect investors' perceptions of the future prospects and financial health of Belite Bio, and Belite Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Belite Stock performance.
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | 2.06 B | ||||
| Shares Outstanding | 32.28 M | ||||
| Price To Book | 15.14 X | ||||
| EBITDA | (39.83 M) | ||||
| Cash And Equivalents | 48.7 M | ||||
| Cash Per Share | 1.96 X | ||||
| Total Debt | 6.31 M | ||||
| Book Value Per Share | 4.58 X | ||||
| Cash Flow From Operations | (29.23 M) | ||||
| Earnings Per Share | (1.18) X | ||||
| Total Asset | 152.13 M | ||||
| Retained Earnings | (107.65 M) | ||||
About Belite Bio Performance
By analyzing Belite Bio's fundamental ratios, stakeholders can gain valuable insights into Belite Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Belite Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Belite Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd. Belite Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.Things to note about Belite Bio ADR performance evaluation
Checking the ongoing alerts about Belite Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Belite Bio ADR help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Net Loss for the year was (36.14 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Belite Bio ADR currently holds about 48.7 M in cash with (29.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.96. | |
| Roughly 55.0% of the company shares are held by company insiders |
- Analyzing Belite Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Belite Bio's stock is overvalued or undervalued compared to its peers.
- Examining Belite Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Belite Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Belite Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Belite Bio's stock. These opinions can provide insight into Belite Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Belite Stock analysis
When running Belite Bio's price analysis, check to measure Belite Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Belite Bio is operating at the current time. Most of Belite Bio's value examination focuses on studying past and present price action to predict the probability of Belite Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Belite Bio's price. Additionally, you may evaluate how the addition of Belite Bio to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |